Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Myositis
•
Dermatomyositis
•
Neurology
How do you approach selecting optimal muscle biopsy site when evaluating a patient for suspected inflammatory myopathy?
Does EMG guide your selection site?
Related Questions
How do you utilize tools such as MMT8 in clinical practice when evaluating myositis?
How do you counsel patients with dermatomyositis on sun protection?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
What is the most appropriate next step in management for a patient with dermatomyositis who is maintained on methotrexate 25 mg weekly but develops disease flare when prednisone is tapered below 10 mg daily and is unable to receive IVIG?
Do you routinely perform muscle biopsies in patients presenting with the classic symptoms of Inclusion Body Myositis along with positive CN1A antibody?
What were your top takeaways in Myositis from ACR Convergence 2025?
Do you consider immunosuppression in patients with a history of Sjogren's disease and clinical features of inclusion body myositis?
Is there a difference in efficacy between steroid-sparing agents like methotrexate, mycophenolate, and azathioprine in the treatment of immune-mediated myopathies?
Do you check IgA levels before starting IVIG for other autoimmune conditions?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
